伏硫西汀治疗抑郁障碍临床疗效评价

目的:分析评价伏硫西汀治疗抑郁障碍的临床疗效及安全性。方法:纳入抑郁障碍患者118例,随机分为艾司西酞普兰组60例和伏硫西汀组58例。分别接受艾司西酞普兰片或伏硫西汀片10~20 mg∕d治疗8周。分别于基线时,治疗2、4、8周末采用汉密尔顿抑郁量表(HAMD)17项版本和临床疗效总评量表(CGI)评价临床疗效。基线期及8周末使用席汉残疾量表(SDS)评估患者的社会功能恢复状况。采用副反应量表(TESS)记录治疗全过程发生的药物不良反应。结果:治疗8周后,CGI-GI评定结果显示,2组总有效率差异无统计学意义(P>0.05)。治疗后各时间点,2组HAMD评分均显著低于同组基线期(P<0.01),但2组各时间点间评分差异无统计学意义(P>0.05)。治疗8周末2组SDS评分均低于治疗前(P<0.01),且伏硫西汀组SDS评分低于艾司西酞普兰组(P<0.01)。2组均未发生严重不良事件,且不良事件发生率差异无统计学意义(P>0.05)。结论:伏硫西汀治疗抑郁障碍在安全性、有效性方面不劣于艾司西酞普兰,可快速有效治疗抑郁障碍患者症状,对社会功能恢复可以起到积极作用。

Clinical Efficacy of Vortioxetine in Treatment of Depressive Disorder

To analyze and evaluate the clinical efficacy and safety of vortioxetine in the treatment of depressive disorder. Methods: A total of 118 patients with depressive disorder were randomly divided into the escitalopram group (n=60) and vortioxetine group (n=58). Patients were treated with either escitalopram or vortioxetine at 10~20 mg/d for 8 weeks. At baseline and at 2, 4, and 8 weeks after treatment, the 17-item Hamilton Depression Scale (HAMD) and the Clinical Global Impression Scale (CGI) were used to assess clinical efficacy. The recovery of social function was assessed by the Sheehan Disability Scale (SDS) at baseline and 8 weeks after treatment. Adverse reactions to drugs were assessed by the Treatment-Emergent Symptoms Scale (TESS) throughout the duration of the study. Results: CGI results at 8 weeks after treatment showed that there was no significant difference between the two groups (P>0.05). At each time point after treatment, the HAMD score of each group was significantly lower than that of the same group at baseline (P<0.01), but there was no significant difference between the two groups at each time point (P>0.05). SDS scores of the two groups after 8 weeks of treatment were significantly improved compared with that at baseline (P<0.01), and the SDS score of the vortioxetine group was significantly lower than that of the escitalopram group (P<0.01). No serious adverse events occurred in either group, and there was no significant difference between the two groups in the incidence of adverse events (P>0.05). Conclusion: Vortioxetine is not inferior to escitalopram in terms of safety and effectiveness in the treatment of depressive disorder. Vortioxetine can quickly and effectively treat the symptoms of depressive disorder and plays a positive role in the recovery of social function.